Training Example: AbbVie (HUMIRA) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

AbbVie (HUMIRA)

(https://humira.com) 📸 Data Snapshot: May 30, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE HUMIRA® (adalimumab) – A Biologic Medication (https://humira.com)
Title

HUMIRA® (adalimumab) – A Biologic Medication

Meta

Find information about HUMIRA® (adalimumab), a biologic medication. See Important Safety Information, including BOXED WARNING and full Prescribing Information.

H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H3 IMPORTANT SAFETY INFORMATION  ABOUT HUMIRA® (adalimumab)1
H3 What is the most important information I should know about HUMIRA?
H3 What should I tell my doctor BEFORE starting HUMIRA?
H3 What should I watch for AFTER starting HUMIRA?
H3 Remember, tell your doctor right away if you have an infection or symptoms of an infection, including:
H3 IMPORTANT SAFETY INFORMATION1
H3 IMPORTANT SAFETY INFORMATION1
H3 IMPORTANT SAFETY INFORMATION1
H3 IMPORTANT SAFETY INFORMATION1
H3 IMPORTANT SAFETY INFORMATION  ABOUT HUMIRA® (adalimumab)1
H3 What is the most important information I should know about HUMIRA?
H3 What should I tell my doctor BEFORE starting HUMIRA?
H3 What should I watch for AFTER starting HUMIRA?
H3 Remember, tell your doctor right away if you have an infection or symptoms of an infection, including:
H4 Choose Your Condition
H4 Choose Your Condition
H5 Conditions HUMIRA Treats
H5 Important Safety Information for Patients
H5 HUMIRA Complete
H5 Information from AbbVie
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER HUMIRA® (adalimumab) for Rheumatoid Arthritis (RA) (https://humira.com/rheumatoid-arthritis/)
Title

HUMIRA® (adalimumab) for Rheumatoid Arthritis (RA)

Meta

Find information about HUMIRA® (adalimumab), a biologic medication. See Important Safety Information, including BOXED WARNING and full Prescribing Information.

H1 HUMIRA for Moderate to Severe Rheumatoid Arthritis (RA)
H2 HUMIRA Results for Rheumatoid Arthritis
H2 Common side effects of HUMIRA
H2 HUMIRA Dosing for Rheumatoid Arthritis
H2 How does HUMIRA work?
H2 Explore a different rheumatoid arthritis treatment option.
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H3 HUMIRA Use1
H3 IMPORTANT SAFETY INFORMATION  ABOUT HUMIRA® (adalimumab)1
H3 What is the most important information I should know about HUMIRA?
H3 What should I tell my doctor BEFORE starting HUMIRA?
H3 What should I watch for AFTER starting HUMIRA?
H3 Remember, tell your doctor right away if you have an infection or symptoms of an infection, including:
H3 HUMIRA Use1
H3 IMPORTANT SAFETY INFORMATION1
H3 IMPORTANT SAFETY INFORMATION1
H3 HUMIRA Use1
H3 IMPORTANT SAFETY INFORMATION1
H3 IMPORTANT SAFETY INFORMATION1
H3 HUMIRA Use1
H3 IMPORTANT SAFETY INFORMATION  ABOUT HUMIRA® (adalimumab)1
H3 What is the most important information I should know about HUMIRA?
H3 What should I tell my doctor BEFORE starting HUMIRA?
H3 What should I watch for AFTER starting HUMIRA?
H3 Remember, tell your doctor right away if you have an infection or symptoms of an infection, including:
H4 Choose Your Condition
H5 Moderate to Severe Rheumatoid Arthritis
H5 Important Safety Information for Patients
H5 HUMIRA Complete
H5 Information from AbbVie
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER HUMIRA® (adalimumab) for Plaque Psoriasis (PS) (https://humira.com/psoriasis/)
Title

HUMIRA® (adalimumab) for Plaque Psoriasis (PS)

Meta

Discover HUMIRA, a biologic treatment option for adults with moderate to severe chronic plaque psoriasis (PS). See Important Safety Information & BOXED WARNING and full Prescribing Information.

H1 What is HUMIRA?
H2 HUMIRA Results for Plaque Psoriasis
H2 Common side effects of HUMIRA
H2 HUMIRA Dosing for Plaque Psoriasis
H2 How does HUMIRA work?
H2 Discover another treatment option.
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H3 HUMIRA Use1
H3 IMPORTANT SAFETY INFORMATION  ABOUT HUMIRA® (adalimumab)1
H3 What is the most important information I should know about HUMIRA?
H3 What should I tell my doctor BEFORE starting HUMIRA?
H3 What should I watch for AFTER starting HUMIRA?
H3 Remember, tell your doctor right away if you have an infection or symptoms of an infection, including:
H3 HUMIRA Use1
H3 IMPORTANT SAFETY INFORMATION  ABOUT HUMIRA® (adalimumab)1
H3 What is the most important information I should know about HUMIRA?
H3 What should I tell my doctor BEFORE starting HUMIRA?
H3 What should I watch for AFTER starting HUMIRA?
H3 Remember, tell your doctor right away if you have an infection or symptoms of an infection, including:
H4 Choose Your Condition
H5 Moderate to Severe Chronic Plaque Psoriasis
H5 Important Safety Information for Patients
H5 HUMIRA Complete
H5 Information from AbbVie
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER HUMIRA® (adalimumab) for Crohn's Disease (CD) (https://humira.com/crohns/)
Title

HUMIRA® (adalimumab) for Crohn's Disease (CD)

Meta

Discover HUMIRA, a biologic treatment option for adults with moderate to severe Crohn's disease (CD). See Important Safety Information & BOXED WARNING and full Prescribing Information.

H1 HUMIRA for Moderate to Severe Crohn’s Disease in Adults
H2 HUMIRA Results for Adult Crohn’s Disease
H2 IN TWO CLINICAL STUDIES
H2 Common side effects of HUMIRA
H2 HUMIRA Dosing for Adult Crohn’s Disease
H2 How does HUMIRA work?
H2 Discover another treatment option.
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H2 Leaving AbbVie Web Site
H3 HUMIRA Use1
H3 IMPORTANT SAFETY INFORMATION  ABOUT HUMIRA® (adalimumab)1
H3 What is the most important information I should know about HUMIRA?
H3 What should I tell my doctor BEFORE starting HUMIRA?
H3 What should I watch for AFTER starting HUMIRA?
H3 Remember, tell your doctor right away if you have an infection or symptoms of an infection, including:
H3 HUMIRA Use1
H3 IMPORTANT SAFETY INFORMATION  ABOUT HUMIRA® (adalimumab)1
H3 What is the most important information I should know about HUMIRA?
H3 What should I tell my doctor BEFORE starting HUMIRA?
H3 What should I watch for AFTER starting HUMIRA?
H3 Remember, tell your doctor right away if you have an infection or symptoms of an infection, including:
H4 Choose Your Condition
H5 Moderate to Severe Crohn’s Disease
H5 Important Safety Information for Patients
H5 HUMIRA Complete
H5 Information from AbbVie
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://humira.com) HUMIRA® (adalimumab) – A Biologic Medication
Reimagine Possible

HUMIRA treats people who have:

Choose Your Condition

[H4] Choose Your Condition

Moderate to SevereRheumatoid Arthritis

Moderate to Severe ChronicPlaque Psoriasis

Moderate to SevereCrohn's Disease

Moderate to SeverePediatric Crohn's Disease

Moderate to SevereUlcerative Colitis

Moderate to Severe Pediatric Ulcerative Colitis

Psoriatic Arthritis

Moderate to SevereHidradenitis Suppurativa

Ankylosing Spondylitis

Moderate to Severe PolyarticularJuvenile Idiopathic Arthritis

Intermediate, Posterior, and Panuveitis Non-Infectious Uveitis

Learn about savings

[H3] IMPORTANT SAFETY INFORMATION
ABOUT HUMIRA® (adalimumab)1
[H3] What is the most important information I should know about HUMIRA?
You should discuss the potential benefits and risks of HUMIRA with your doctor. HUMIRA is a TNF blocker medicine that can lower the ability of your immune system to fight infections. You should not start taking HUMIRA if you have any kind of infection unless your doctor says it is okay.
Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting HUMIRA, and check you closely for signs and symptoms of TB during treatment with HUMIRA, even if your TB test was negative. If your doctor feels you are at risk, you may be treated with medicine for TB.
Cancer. For children and adults taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. There have been cases of unusual cancers in children, teenagers, and young adults using TNF blockers. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers including HUMIRA, your chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated; tell your doctor if you have a bump or open sore that doesn’t heal.
[H3] What should I tell my doctor BEFORE starting HUMIRA?
Tell your doctor about all of your health conditions, including if you:
Have an infection, are being treated for infection, or have symptoms of an infection
Get a lot of infections or infections that keep coming back
Have diabetes
Have TB or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB
Live or have lived in an area (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections, such as histoplasmosis, coccidioidomycosis, or blastomycosis. These infections may happen or become more severe if you use HUMIRA. Ask your doctor if you are unsure if you have lived in these areas
Have or have had hepatitis B
Are scheduled for major surgery
Have or have had cancer
Have numbness or tingling or a nervous system disease such as multiple sclerosis or Guillain-Barré syndrome
Have or had heart failure
Have recently received or are scheduled to receive a vaccine. HUMIRA patients may receive vaccines, except for live vaccines. Children should be brought up to date on all vaccines before starting HUMIRA
Are allergic to rubber, latex, or any HUMIRA ingredients
Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed
Have a baby and you were using HUMIRA during your pregnancy. Tell your baby’s doctor before your baby receives any vaccines
Also tell your doctor about all the medicines you take. You should not take HUMIRA with ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab). Tell your doctor if you have ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).
[H3] What should I watch for AFTER starting HUMIRA?
HUMIRA can cause serious side effects, including:
Serious infections. These include TB and infections caused by viruses, fungi, or bacteria. Symptoms related to TB include a cough, low-grade fever, weight loss, or loss of body fat and muscle.
Hepatitis B infection in carriers of the virus. Symptoms include muscle aches, feeling very tired, dark urine, skin or eyes that look yellow, little or no appetite, vomiting, clay-colored bowel movements, fever, chills, stomach discomfort, and skin rash.
Allergic reactions. Symptoms of a serious allergic reaction include hives, trouble breathing, and swelling of your face, eyes, lips, or mouth.
Nervous system problems. Signs and symptoms include numbness or tingling, problems with your vision, weakness in your arms or legs, and dizziness.
Blood problems (decreased blood cells that help fight infections or stop bleeding). Symptoms include a fever that does not go away, bruising or bleeding very easily, or looking very pale.
Heart failure (new or worsening). Symptoms include shortness of breath, swelling of your ankles or feet, and sudden weight gain.
Immune reactions including a lupus-like syndrome. Symptoms include chest discomfort or pain that does not go away, shortness of breath, joint pain, or rash on your cheeks or arms that gets worse in the sun.
Liver problems. Symptoms include feeling very tired, skin or eyes that look yellow, poor appetite or vomiting, and pain on the right side of your stomach (abdomen). These problems can lead to liver failure and death.
Psoriasis (new or worsening). Symptoms include red scaly patches or raised bumps that are filled with pus.
Call your doctor or get medical care right away if you develop any of the above symptoms.
Common side effects of HUMIRA include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your doctor if you have any side effect that bothers you or that does not go away.
[H3] Remember, tell your doctor right away if you have an infection or symptoms of an infection, including:
Fever, sweats, or chills
Muscle aches
Cough
Shortness of breath
Blood in phlegm
Weight loss
Warm, red, or painful skin or sores on your body
Diarrhea or stomach pain
Burning when you urinate
Urinating more often than normal
Feeling very tired
HUMIRA is given by injection under the skin.
This is the most important information to know about HUMIRA. For more information, talk to your health care provider.
Uses
HUMIRA is a prescription medicine used:
To reduce the signs and symptoms of:
Moderate to severe rheumatoid arthritis (RA) in adults. HUMIRA can be used alone, with methotrexate, or with certain other medicines. HUMIRA may prevent further damage to your bones and joints and may help your ability to perform daily activities.
Moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 years of age and older. HUMIRA can be used alone or with methotrexate.
Psoriatic arthritis (PsA) in adults. HUMIRA can be used alone or with certain other medicines. HUMIRA may prevent further damage to your bones and joints and may help your ability to perform daily activities.
Ankylosing spondylitis (AS) in adults.
Moderate to severe hidradenitis suppurativa (HS) in people 12 years and older.
To treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of age and older.
To treat moderate to severe ulcerative colitis (UC) in adults and children 5 years of age and older. It is not known if HUMIRA is effective in people who stopped responding to or could not tolerate anti-TNF medicines.
To treat moderate to severe chronic plaque psoriasis (Ps) in adults who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.
To treat non-infectious intermediate (middle part of the eye), posterior (back of the eye), and panuveitis (all parts of the eye) in adults and children 2 years of age and older.
US-HUM-210186

Please see the Full Prescribing Information, including the Medication Guide, for HUMIRA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.

Legal Notices. ©2024 AbbVie. All rights reserved. If you have any questions about AbbVie’s HUMIRA.com website that have not been answered click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.
Reference: 1. HUMIRA Injection [package insert]. North Chicago, IL: AbbVie Inc.

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience, and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy, for which AbbVie has no responsibility.
Conversely, the presence of this link does not imply the linked site's endorsement of HUMIRA.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-HUM-220495

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.
Conversely, the presence of this link does not imply the linked site's endorsement of HUMIRA.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-HUM-220495

[H4] Choose Your Condition

Moderate to SevereRheumatoid Arthritis

Moderate to Severe ChronicPlaque Psoriasis

Moderate to SevereCrohn's Disease

Moderate to SeverePediatric Crohn's Disease

Moderate to SevereUlcerative Colitis

Moderate to Severe Pediatric Ulcerative Colitis

Psoriatic Arthritis

Moderate to SevereHidradenitis Suppurativa

Ankylosing Spondylitis

Moderate to Severe PolyarticularJuvenile Idiopathic Arthritis

Intermediate, Posterior, and PanuveitisNon-Infectious Uveitis

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.
Conversely, the presence of this link does not imply the linked site's endorsement of HUMIRA.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-HUM-240061

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.
Conversely, the presence of this link does not imply the linked site's endorsement of HUMIRA.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-HUM-250185

[H3] IMPORTANT SAFETY INFORMATION1
You should not start taking HUMIRA if you have any kind of infection unless your doctor says it is okay. Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting HUMIRA, and check you closely for signs and symptoms of TB during treatment with HUMIRA, even if your TB test was negative. If your doctor feels you are at risk, you may be treated with medicine for TB.

[H3] IMPORTANT SAFETY INFORMATION1
You should not start taking HUMIRA if you have any kind of infection unless your doctor says it is okay. Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections.

[H3] IMPORTANT SAFETY INFORMATION1
You should not start taking HUMIRA if you have any kind of infection unless your doctor says it is okay. Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting HUMIRA, and check you closely for si
15000 chars
SUB-PAGE (https://humira.com/rheumatoid-arthritis/) HUMIRA® (adalimumab) for Rheumatoid Arthritis (RA)
[H1] HUMIRA for Moderate to Severe Rheumatoid Arthritis (RA)

[H1] HUMIRA for Moderate to Severe Rheumatoid Arthritis (RA)

[H1] What is HUMIRA?

HUMIRA is a prescription medicine used alone, with methotrexate, or with certain other medicines to reduce the signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adults, may prevent further damage to your bones and joints, and may help your ability to perform daily activities.

[H2] HUMIRA Results for Rheumatoid Arthritis

In a study of moderate to severe RA patients diagnosed for an average of 11 years who added HUMIRA to methotrexate.

People with RA signs and symptoms who saw improvement

[IMG: 63% humira + methotrexate]

[IMG: 30% methotrexate alone]

When compared with methotrexate alone in a clinical study, more people taking HUMIRA and methotrexate saw a 20% improvement in the signs and symptoms of RA at 6 months.

In a separate study of patients with moderate to severe RA (diagnosed for less than 3 years and not previously treated with methotrexate).

People with no further joint damage as seen on X-ray 1 year after treatment

[IMG: 64% humira + methotrexate]

[IMG: 37% methotrexate alone]

Individual results may vary.

[H2] Common side effects of HUMIRA

Common side effects of HUMIRA include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your doctor if you have any side effect that bothers you or that does not go away.
Read about the Important Safety Information for HUMIRA.

[IMG: HUMIRA® pen]

[H2] HUMIRA Dosing for Rheumatoid Arthritis

It’s important to use proper injection technique and follow the dosing schedule for your treatment with HUMIRA.
The recommended dose is 40 mg every other week.
Some patients not taking methotrexate may benefit from increasing the dosage of HUMIRA to 40 mg every week or 80 mg every other week. Always follow your doctor's instructions about when and how often to take HUMIRA.*
HUMIRA is given by an injection under the skin.
Your first dose must be given under the supervision of a health care professional. Make sure you have been shown how to inject HUMIRA before you do it yourself. If your doctor determines that it's ok, HUMIRA can be taken at home. Remember to keep your HUMIRA refrigerated in its original container until ready for use.
You should continue taking HUMIRA as directed by your doctor. Remember, HUMIRA is a treatment, not a cure. Your doctor can tell you if and when you should stop taking HUMIRA.
For more information, refer to the Patient Instructions for Use and the Medication Guide located inside the HUMIRA carton, and within the Full Prescribing Information. If you experience any adverse reactions or discomfort when taking HUMIRA, discuss them with your doctor right away.

*Refer to the Patient Instructions for Use to learn about the HUMIRA Pen and prefilled syringe.

[H2] How does HUMIRA work?

The protein TNF-alpha is believed to be part of your body’s natural processes involved in creating inflammation, and in some cases, excess inflammation. When used as prescribed, HUMIRA targets and blocks TNF-alpha, which plays an important role in the inflammation and potential development of permanent joint damage associated with moderate to severe RA.

[H2] Explore a different rheumatoid arthritis treatment option.

Learn about a once-daily pill for adults with moderate to severe rheumatoid arthritis who have already tried a TNF blocker like HUMIRA.

See what’s possible

[H3] HUMIRA Use1
HUMIRA is a prescription medicine used alone, with methotrexate, or with certain other medicines to reduce the signs and symptoms of moderate to severe rheumatoid arthritis in adults, may prevent further damage to your bones and joints, and may help your ability to perform daily activities.

[H3] IMPORTANT SAFETY INFORMATION
ABOUT HUMIRA® (adalimumab)1
[H3] What is the most important information I should know about HUMIRA?
You should discuss the potential benefits and risks of HUMIRA with your doctor. HUMIRA is a TNF blocker medicine that can lower the ability of your immune system to fight infections. You should not start taking HUMIRA if you have any kind of infection unless your doctor says it is okay.
Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting HUMIRA, and check you closely for signs and symptoms of TB during treatment with HUMIRA, even if your TB test was negative. If your doctor feels you are at risk, you may be treated with medicine for TB.
Cancer. For children and adults taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. There have been cases of unusual cancers in children, teenagers, and young adults using TNF blockers. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers including HUMIRA, your chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated; tell your doctor if you have a bump or open sore that doesn’t heal.
[H3] What should I tell my doctor BEFORE starting HUMIRA?
Tell your doctor about all of your health conditions, including if you:
Have an infection, are being treated for infection, or have symptoms of an infection
Get a lot of infections or infections that keep coming back
Have diabetes
Have TB or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB
Live or have lived in an area (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections, such as histoplasmosis, coccidioidomycosis, or blastomycosis. These infections may happen or become more severe if you use HUMIRA. Ask your doctor if you are unsure if you have lived in these areas
Have or have had hepatitis B
Are scheduled for major surgery
Have or have had cancer
Have numbness or tingling or a nervous system disease such as multiple sclerosis or Guillain-Barré syndrome
Have or had heart failure
Have recently received or are scheduled to receive a vaccine. HUMIRA patients may receive vaccines, except for live vaccines. Children should be brought up to date on all vaccines before starting HUMIRA
Are allergic to rubber, latex, or any HUMIRA ingredients
Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed
Have a baby and you were using HUMIRA during your pregnancy. Tell your baby’s doctor before your baby receives any vaccines
Also tell your doctor about all the medicines you take. You should not take HUMIRA with ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab). Tell your doctor if you have ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).
[H3] What should I watch for AFTER starting HUMIRA?
HUMIRA can cause serious side effects, including:
Serious infections. These include TB and infections caused by viruses, fungi, or bacteria. Symptoms related to TB include a cough, low-grade fever, weight loss, or loss of body fat and muscle.
Hepatitis B infection in carriers of the virus. Symptoms include muscle aches, feeling very tired, dark urine, skin or eyes that look yellow, little or no appetite, vomiting, clay-colored bowel movements, fever, chills, stomach discomfort, and skin rash.
Allergic reactions. Symptoms of a serious allergic reaction include hives, trouble breathing, and swelling of your face, eyes, lips, or mouth.
Nervous system problems. Signs and symptoms include numbness or tingling, problems with your vision, weakness in your arms or legs, and dizziness.
Blood problems (decreased blood cells that help fight infections or stop bleeding). Symptoms include a fever that does not go away, bruising or bleeding very easily, or looking very pale.
Heart failure (new or worsening). Symptoms include shortness of breath, swelling of your ankles or feet, and sudden weight gain.
Immune reactions including a lupus-like syndrome. Symptoms include chest discomfort or pain that does not go away, shortness of breath, joint pain, or rash on your cheeks or arms that gets worse in the sun.
Liver problems. Symptoms include feeling very tired, skin or eyes that look yellow, poor appetite or vomiting, and pain on the right side of your stomach (abdomen). These problems can lead to liver failure and death.
Psoriasis (new or worsening). Symptoms include red scaly patches or raised bumps that are filled with pus.
Call your doctor or get medical care right away if you develop any of the above symptoms.
Common side effects of HUMIRA include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your doctor if you have any side effect that bothers you or that does not go away.
[H3] Remember, tell your doctor right away if you have an infection or symptoms of an infection, including:
Fever, sweats, or chills
Muscle aches
Cough
Shortness of breath
Blood in phlegm
Weight loss
Warm, red, or painful skin or sores on your body
Diarrhea or stomach pain
Burning when you urinate
Urinating more often than normal
Feeling very tired
HUMIRA is given by injection under the skin.
This is the most important information to know about HUMIRA. For more information, talk to your health care provider.
Uses
HUMIRA is a prescription medicine used:
To reduce the signs and symptoms of:
Moderate to severe rheumatoid arthritis (RA) in adults. HUMIRA can be used alone, with methotrexate, or with certain other medicines. HUMIRA may prevent further damage to your bones and joints and may help your ability to perform daily activities.
Moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 years of age and older. HUMIRA can be used alone or with methotrexate.
Psoriatic arthritis (PsA) in adults. HUMIRA can be used alone or with certain other medicines. HUMIRA may prevent further damage to your bones and joints and may help your ability to perform daily activities.
Ankylosing spondylitis (AS) in adults.
Moderate to severe hidradenitis suppurativa (HS) in people 12 years and older.
To treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of age and older.
To treat moderate to severe ulcerative colitis (UC) in adults and children 5 years of age and older. It is not known if HUMIRA is effective in people who stopped responding to or could not tolerate anti-TNF medicines.
To treat moderate to severe chronic plaque psoriasis (Ps) in adults who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.
To treat non-infectious intermediate (middle part of the eye), posterior (back of the eye), and panuveitis (all parts of the eye) in adults and children 2 years of age and older.
US-HUM-210186

Please see the Full Prescribing Information, including the Medication Guide, for HUMIRA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.

Legal Notices. ©2024 AbbVie. All rights reserved. If you have any questions about AbbVie’s HUMIRA.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.
Reference: 1. HUMIRA Injection [package insert]. North Chicago, IL: AbbVie Inc.

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.
Conversely, the presence of this link does not imply the linked site's endorsement of HUMIRA.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-HUM-250185

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.
Conversely, the presence of this link does not imply the linked site's endorsement of HUMIRA.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-HUM-220495

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience, and the inclusion of any link does not imply the endorsement o
15000 chars
SUB-PAGE (https://humira.com/psoriasis/) HUMIRA® (adalimumab) for Plaque Psoriasis (PS)
HUMIRA for Moderate to Severe Chronic Plaque Psoriasis (Ps)

HUMIRA for Moderate to Severe Chronic Plaque Psoriasis (Ps)

[H1] What is HUMIRA?

HUMIRA is a prescription medicine used to treat adults with moderate to severe chronic plaque psoriasis (Ps) who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.

[H2] HUMIRA Results for Plaque Psoriasis

In clinical trials, most adults taking HUMIRA had clear or almost clear skin, and many saw 75% or more skin clearance in just 4 months.
Individual results may vary.

[H2] Common side effects of HUMIRA

Common side effects of HUMIRA include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your doctor if you have any side effect that bothers you or that does not go away.
Read about the Important Safety Information for HUMIRA.

[IMG: HUMIRA® pen]

[H2] HUMIRA Dosing for Plaque Psoriasis

Important: You must pay attention to your starting dose—it is different than your maintenance dose and is a critical part of taking HUMIRA as prescribed. Always follow your doctor’s instructions about when and how often to take HUMIRA.*
HUMIRA is given by injection under the skin.

Starting dose
Administered on Day 1 only: 80 mg


Maintenance dose
Can be administered at home on Day 8 and every other week thereafter: 40 mg

Your first dose of HUMIRA must be given under the supervision of a health care professional. Make sure you have been shown how to inject HUMIRA before you do it yourself. Remember to keep your HUMIRA refrigerated in its original container until ready for use.
You should continue taking HUMIRA as directed by your doctor. Remember, HUMIRA is a treatment, not a cure. Your doctor can tell you if and when you should stop taking HUMIRA.
For more information, refer to the Patient Instructions for Use and the Medication Guide located inside the HUMIRA carton, and within the Full Prescribing Information. If you experience any adverse reactions or discomfort when taking HUMIRA, discuss them with your doctor right away.

*Refer to the Patient Instructions for Use to learn about the HUMIRA Pen and prefilled syringe.

[H2] How does HUMIRA work?

The protein TNF-alpha is believed to be part of your body’s natural processes involved in creating inflammation, and in some cases, excess inflammation. When used as prescribed, HUMIRA targets and blocks TNF-alpha, which can help reduce excess inflammation associated with Ps.

[H2] Discover another treatment option.

Explore a different treatment for adults with moderate to severe chronic plaque psoriasis.

See what’s possible

[H3] HUMIRA Use1
HUMIRA is a prescription medicine used to treat adults with moderate to severe chronic plaque psoriasis who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.

[H3] IMPORTANT SAFETY INFORMATION
ABOUT HUMIRA® (adalimumab)1
[H3] What is the most important information I should know about HUMIRA?
You should discuss the potential benefits and risks of HUMIRA with your doctor. HUMIRA is a TNF blocker medicine that can lower the ability of your immune system to fight infections. You should not start taking HUMIRA if you have any kind of infection unless your doctor says it is okay.
Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting HUMIRA, and check you closely for signs and symptoms of TB during treatment with HUMIRA, even if your TB test was negative. If your doctor feels you are at risk, you may be treated with medicine for TB.
Cancer. For children and adults taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. There have been cases of unusual cancers in children, teenagers, and young adults using TNF blockers. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers including HUMIRA, your chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated; tell your doctor if you have a bump or open sore that doesn’t heal.
[H3] What should I tell my doctor BEFORE starting HUMIRA?
Tell your doctor about all of your health conditions, including if you:
Have an infection, are being treated for infection, or have symptoms of an infection
Get a lot of infections or infections that keep coming back
Have diabetes
Have TB or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB
Live or have lived in an area (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections, such as histoplasmosis, coccidioidomycosis, or blastomycosis. These infections may happen or become more severe if you use HUMIRA. Ask your doctor if you are unsure if you have lived in these areas
Have or have had hepatitis B
Are scheduled for major surgery
Have or have had cancer
Have numbness or tingling or a nervous system disease such as multiple sclerosis or Guillain-Barré syndrome
Have or had heart failure
Have recently received or are scheduled to receive a vaccine. HUMIRA patients may receive vaccines, except for live vaccines. Children should be brought up to date on all vaccines before starting HUMIRA
Are allergic to rubber, latex, or any HUMIRA ingredients
Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed
Have a baby and you were using HUMIRA during your pregnancy. Tell your baby’s doctor before your baby receives any vaccines
Also tell your doctor about all the medicines you take. You should not take HUMIRA with ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab). Tell your doctor if you have ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).
[H3] What should I watch for AFTER starting HUMIRA?
HUMIRA can cause serious side effects, including:
Serious infections. These include TB and infections caused by viruses, fungi, or bacteria. Symptoms related to TB include a cough, low-grade fever, weight loss, or loss of body fat and muscle.
Hepatitis B infection in carriers of the virus. Symptoms include muscle aches, feeling very tired, dark urine, skin or eyes that look yellow, little or no appetite, vomiting, clay-colored bowel movements, fever, chills, stomach discomfort, and skin rash.
Allergic reactions. Symptoms of a serious allergic reaction include hives, trouble breathing, and swelling of your face, eyes, lips, or mouth.
Nervous system problems. Signs and symptoms include numbness or tingling, problems with your vision, weakness in your arms or legs, and dizziness.
Blood problems (decreased blood cells that help fight infections or stop bleeding). Symptoms include a fever that does not go away, bruising or bleeding very easily, or looking very pale.
Heart failure (new or worsening). Symptoms include shortness of breath, swelling of your ankles or feet, and sudden weight gain.
Immune reactions including a lupus-like syndrome. Symptoms include chest discomfort or pain that does not go away, shortness of breath, joint pain, or rash on your cheeks or arms that gets worse in the sun.
Liver problems. Symptoms include feeling very tired, skin or eyes that look yellow, poor appetite or vomiting, and pain on the right side of your stomach (abdomen). These problems can lead to liver failure and death.
Psoriasis (new or worsening). Symptoms include red scaly patches or raised bumps that are filled with pus.
Call your doctor or get medical care right away if you develop any of the above symptoms.
Common side effects of HUMIRA include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your doctor if you have any side effect that bothers you or that does not go away.
[H3] Remember, tell your doctor right away if you have an infection or symptoms of an infection, including:
Fever, sweats, or chills
Muscle aches
Cough
Shortness of breath
Blood in phlegm
Weight loss
Warm, red, or painful skin or sores on your body
Diarrhea or stomach pain
Burning when you urinate
Urinating more often than normal
Feeling very tired
HUMIRA is given by injection under the skin.
This is the most important information to know about HUMIRA. For more information, talk to your health care provider.
Uses
HUMIRA is a prescription medicine used:
To reduce the signs and symptoms of:
Moderate to severe rheumatoid arthritis (RA) in adults. HUMIRA can be used alone, with methotrexate, or with certain other medicines. HUMIRA may prevent further damage to your bones and joints and may help your ability to perform daily activities.
Moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 years of age and older. HUMIRA can be used alone or with methotrexate.
Psoriatic arthritis (PsA) in adults. HUMIRA can be used alone or with certain other medicines. HUMIRA may prevent further damage to your bones and joints and may help your ability to perform daily activities.
Ankylosing spondylitis (AS) in adults.
Moderate to severe hidradenitis suppurativa (HS) in people 12 years and older.
To treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of age and older.
To treat moderate to severe ulcerative colitis (UC) in adults and children 5 years of age and older. It is not known if HUMIRA is effective in people who stopped responding to or could not tolerate anti-TNF medicines.
To treat moderate to severe chronic plaque psoriasis (Ps) in adults who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.
To treat non-infectious intermediate (middle part of the eye), posterior (back of the eye), and panuveitis (all parts of the eye) in adults and children 2 years of age and older.
US-HUM-210186

Please see the Full Prescribing Information, including the Medication Guide, for HUMIRA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.

Legal Notices. ©2024 AbbVie. All rights reserved. If you have any questions about AbbVie’s HUMIRA.com website that have not been answered click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.
Reference: 1. HUMIRA Injection [package insert]. North Chicago, IL: AbbVie Inc.

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.
Conversely, the presence of this link does not imply the linked site's endorsement of HUMIRA.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-HUM-210631

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience, and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy, for which AbbVie has no responsibility.
Conversely, the presence of this link does not imply the linked site's endorsement of HUMIRA.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-HUM-220495

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.
Conversely, the presence of this link does not imply the linked site's endorsement of HUMIRA.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-HUM-220495

[H4] Choose Your Condition

Moderate to SevereRheumatoid Arthritis

Moderate to Severe ChronicPlaque Psoriasis

Moderate to SevereCrohn's Disease

Moderate to SeverePediatric Crohn's Disease

Moderate to SevereUlcerative Colitis

Moderate to Severe Pediatric Ulcerative Colitis

Psoriatic Arthritis

Moderate to SevereHidradenitis Suppurativa

An
15000 chars
SUB-PAGE (https://humira.com/crohns/) HUMIRA® (adalimumab) for Crohn's Disease (CD)
[H1] HUMIRA for Moderate to Severe Crohn’s Disease in Adults

[H1] HUMIRA for Moderate to Severe Crohn’s Disease in Adults

[H1] What is HUMIRA?

HUMIRA is a prescription medicine used to treat moderate to severe Crohn’s disease in adults and children 6 years of age and older.

[H2] HUMIRA Results for Adult Crohn’s Disease

In clinical studies at 4 weeks, many Crohn’s patients on HUMIRA achieved remission (few or no symptoms) and a majority saw symptom relief.

[H2] IN TWO CLINICAL STUDIES

PATIENTS ACHIEVED REMISSION AT 4 WEEKS

Taking HUMIRA®

Taking placebo

STUDY 1

[IMG: 36%]

[IMG: 12%]

STUDY 2

[IMG: 21%]

[IMG: 7%]

PATIENTS SAW SYMPTOM RELIEF AT 4 WEEKS

Taking HUMIRA®

Taking placebo

STUDY 1

[IMG: 58%]

[IMG: 34%]

STUDY 2

[IMG: 52%]

[IMG: 34%]

HUMIRA has helped many people notice a significant difference in their symptoms in as little as 4 weeks.
Individual results may vary.
Only you and your doctor can decide if HUMIRA is right for you. Patients who do not see results within 12 weeks should talk to their doctor.

[H2] Common side effects of HUMIRA

Common side effects of HUMIRA include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your doctor if you have any side effect that bothers you or that does not go away.
Read about the Important Safety Information for HUMIRA

[IMG: HUMIRA® pen]

[H2] HUMIRA Dosing for Adult Crohn’s Disease

Important: You must pay attention to your starting dose–it is different than your maintenance dose and is a critical part of taking HUMIRA as prescribed. Always follow your doctor’s instructions about when and how often to take HUMIRA.*
HUMIRA is given by injection under the skin.

Starting dose
Starting doses are higher doses to help you quickly reach an effective concentration of medicine in your body and they are typically administered on Day 1 and Day 15 of your treatment with HUMIRA. An initial Day 1 dose is 160 mg (given in one day or split over two consecutive days) followed by one 80 mg on Day 15.

Maintenance Dose
After that, you’ll continue with one 40 mg maintenance dose every other week starting on Day 29. This lower dose is meant to help you keep the amount of HUMIRA in your body at a stable level.

Your first dose of HUMIRA must be given under the supervision of a health care professional. Make sure you have been shown how to inject HUMIRA before you do it yourself. Remember to keep your HUMIRA refrigerated in its original container until ready for use.
You should continue taking HUMIRA as directed by your doctor. Remember, HUMIRA is a treatment, not a cure. Your doctor can tell you if and when you should stop taking HUMIRA.
For more information, refer to the Patient Instructions for Use and the Medication Guide located inside the HUMIRA carton, and within the Full Prescribing Information. If you experience any adverse reactions or discomfort when taking HUMIRA, discuss them with your doctor right away.
*Refer to the Patient Instructions for Use to learn about the HUMIRA Pen and prefilled syringe.

[H2] How does HUMIRA work?

The protein TNF-alpha is believed to be part of your body’s natural processes involved in creating inflammation, and in some cases, excess inflammation. When used as prescribed, HUMIRA targets and blocks TNF-alpha, which can help reduce the excess inflammation associated with Crohn’s disease.

[H2] Discover another treatment option.

Explore a different treatment for adults with moderate to severe Crohn's disease.

See what’s possible

[H3] HUMIRA Use1
HUMIRA is a prescription medicine used to treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of age and older.

[H3] IMPORTANT SAFETY INFORMATION
ABOUT HUMIRA® (adalimumab)1
[H3] What is the most important information I should know about HUMIRA?
You should discuss the potential benefits and risks of HUMIRA with your doctor. HUMIRA is a TNF blocker medicine that can lower the ability of your immune system to fight infections. You should not start taking HUMIRA if you have any kind of infection unless your doctor says it is okay.
Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting HUMIRA, and check you closely for signs and symptoms of TB during treatment with HUMIRA, even if your TB test was negative. If your doctor feels you are at risk, you may be treated with medicine for TB.
Cancer. For children and adults taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. There have been cases of unusual cancers in children, teenagers, and young adults using TNF blockers. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers including HUMIRA, your chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated; tell your doctor if you have a bump or open sore that doesn’t heal.
[H3] What should I tell my doctor BEFORE starting HUMIRA?
Tell your doctor about all of your health conditions, including if you:
Have an infection, are being treated for infection, or have symptoms of an infection
Get a lot of infections or infections that keep coming back
Have diabetes
Have TB or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB
Live or have lived in an area (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections, such as histoplasmosis, coccidioidomycosis, or blastomycosis. These infections may happen or become more severe if you use HUMIRA. Ask your doctor if you are unsure if you have lived in these areas
Have or have had hepatitis B
Are scheduled for major surgery
Have or have had cancer
Have numbness or tingling or a nervous system disease such as multiple sclerosis or Guillain-Barré syndrome
Have or had heart failure
Have recently received or are scheduled to receive a vaccine. HUMIRA patients may receive vaccines, except for live vaccines. Children should be brought up to date on all vaccines before starting HUMIRA
Are allergic to rubber, latex, or any HUMIRA ingredients
Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed
Have a baby and you were using HUMIRA during your pregnancy. Tell your baby’s doctor before your baby receives any vaccines
Also tell your doctor about all the medicines you take. You should not take HUMIRA with ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab). Tell your doctor if you have ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).
[H3] What should I watch for AFTER starting HUMIRA?
HUMIRA can cause serious side effects, including:
Serious infections. These include TB and infections caused by viruses, fungi, or bacteria. Symptoms related to TB include a cough, low-grade fever, weight loss, or loss of body fat and muscle.
Hepatitis B infection in carriers of the virus. Symptoms include muscle aches, feeling very tired, dark urine, skin or eyes that look yellow, little or no appetite, vomiting, clay-colored bowel movements, fever, chills, stomach discomfort, and skin rash.
Allergic reactions. Symptoms of a serious allergic reaction include hives, trouble breathing, and swelling of your face, eyes, lips, or mouth.
Nervous system problems. Signs and symptoms include numbness or tingling, problems with your vision, weakness in your arms or legs, and dizziness.
Blood problems (decreased blood cells that help fight infections or stop bleeding). Symptoms include a fever that does not go away, bruising or bleeding very easily, or looking very pale.
Heart failure (new or worsening). Symptoms include shortness of breath, swelling of your ankles or feet, and sudden weight gain.
Immune reactions including a lupus-like syndrome. Symptoms include chest discomfort or pain that does not go away, shortness of breath, joint pain, or rash on your cheeks or arms that gets worse in the sun.
Liver problems. Symptoms include feeling very tired, skin or eyes that look yellow, poor appetite or vomiting, and pain on the right side of your stomach (abdomen). These problems can lead to liver failure and death.
Psoriasis (new or worsening). Symptoms include red scaly patches or raised bumps that are filled with pus.
Call your doctor or get medical care right away if you develop any of the above symptoms.
Common side effects of HUMIRA include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your doctor if you have any side effect that bothers you or that does not go away.
[H3] Remember, tell your doctor right away if you have an infection or symptoms of an infection, including:
Fever, sweats, or chills
Muscle aches
Cough
Shortness of breath
Blood in phlegm
Weight loss
Warm, red, or painful skin or sores on your body
Diarrhea or stomach pain
Burning when you urinate
Urinating more often than normal
Feeling very tired
HUMIRA is given by injection under the skin.
This is the most important information to know about HUMIRA. For more information, talk to your health care provider.
Uses
HUMIRA is a prescription medicine used:
To reduce the signs and symptoms of:
Moderate to severe rheumatoid arthritis (RA) in adults. HUMIRA can be used alone, with methotrexate, or with certain other medicines. HUMIRA may prevent further damage to your bones and joints and may help your ability to perform daily activities.
Moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 years of age and older. HUMIRA can be used alone or with methotrexate.
Psoriatic arthritis (PsA) in adults. HUMIRA can be used alone or with certain other medicines. HUMIRA may prevent further damage to your bones and joints and may help your ability to perform daily activities.
Ankylosing spondylitis (AS) in adults.
Moderate to severe hidradenitis suppurativa (HS) in people 12 years and older.
To treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of age and older.
To treat moderate to severe ulcerative colitis (UC) in adults and children 5 years of age and older. It is not known if HUMIRA is effective in people who stopped responding to or could not tolerate anti-TNF medicines.
To treat moderate to severe chronic plaque psoriasis (Ps) in adults who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.
To treat non-infectious intermediate (middle part of the eye), posterior (back of the eye), and panuveitis (all parts of the eye) in adults and children 2 years of age and older.
US-HUM-210186

Please see the Full Prescribing Information, including the Medication Guide, for HUMIRA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.

Legal Notices. ©2024 AbbVie. All rights reserved. If you have any questions about AbbVie’s HUMIRA.com website that have not been answered click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.
Reference: 1. HUMIRA Injection [package insert]. North Chicago, IL: AbbVie Inc.

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.
Conversely, the presence of this link does not imply the linked site's endorsement of HUMIRA.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-HUM-220495

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.
Conversely, the presence of this link does not imply the linked site's endorsement of HUMIRA.com or AbbVie.
Do you wish to leave this site?

Yes

No

US-HUM-250185

[H2] Leaving AbbVie Web Site

You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these li
15000 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
0Review mentions (all pages)
7External proof links (all pages)
PageReviewsProof links
/ (home) 0 1
/rheumatoid-arthritis/ 0 2
/psoriasis/ 0 2
/crohns/ 0 2
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/rheumatoid-arthritis/ — no schema detected (entity gap)
/psoriasis/ — no schema detected (entity gap)
/crohns/ — no schema detected (entity gap)

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: AbbVie (HUMIRA) (humira.com)

https://humira.com 📍 Industry: Medical Devices, Pharma & Biotech
16 BS / 100

A high-substance pharmaceutical site that prioritizes clinical data and regulatory safety disclosures over marketing hyperbole. The low BS score reflects the heavy oversight and requirement for forensic proof inherent in the pharmaceutical industry.

Info Density Power-words vs. Substance ratio.
4
13% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
1
5% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
0
0% BS
Commodity Fingerprint Detection of industry clichés/templates.
4
27% BS
Identity & Authority Expert verifiability & Schema depth.
7
47% BS

Fix the empty H1 tag on the homepage to clearly state the brand and primary indication for better SEO and accessibility. Implement Organization and Person schema to formally link AbbVie and medical leadership to the website’s claims. Consolidate the navigation-based ‘Leaving AbbVie’ H2 tags into a single modal to clean up the heading hierarchy. Update copyright and study dates to 2025 or 2026 to avoid the ‘aging’ content penalty as current data approaches the 36-month stale threshold.

The site perfectly matches the Medical and Pharmaceutical category, specifically targeting biologic therapies. All content is focused on the prescription medication adalimumab and its clinical indications for chronic inflammatory conditions.

“The score of 16 is driven by the extreme density of clinical data and the total absence of trust theatre (zero review counts without verification). Points were only added due to the absence of structured data schema and technical errors in heading hierarchy like the missing H1 and repetitive disclaimer H2s. Commodity fingerprint scores were minimized because technical jargon was used for functional clinical descriptions.”

Verified Analysis Date: May 30, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Brand AI Reputation